TRAIL-induced apoptosis: Between tumor therapy and immunopathology

Annals of the New York Academy of Sciences

Volumn 1171, Issue , 2009, Pages 50-58

  Corazza, Nadia ^a   Kassahn, Daniela ^a   Jakob, Sabine ^a   Badmann, Anastasia ^a   Brunner, Thomas ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Apoptosis; Bim; Hepatocyte; Jun kinase; Liver injury; TRAIL; Tumor

Indexed keywords

ANTIINFECTIVE AGENT; BORTEZOMIB; CASPASE 8; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; ETOPOSIDE; FAS LIGAND; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOPROTEGERIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER THERAPY; CELL CYCLE ARREST; COLON CARCINOMA; CONFERENCE PAPER; GAMMA IRRADIATION; GLIOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPATHOLOGY; IN VIVO STUDY; LIVER CELL; LIVER INJURY; LIVER METASTASIS; LIVER TOXICITY; MITOCHONDRION; MULTIPLE MYELOMA; NONHUMAN; SHOCK; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 69149092108     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04905.x     Document Type: Conference Paper

References (56)

1. Pitti, R.M. et al. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 : 12687 12690.
2. Wiley, S.R. et al. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 : 673 682.
3. Mariani, S.M. P.H. Krammer. 1998. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 28 : 973 982.
4. Bodmer, J.L. et al. 2000. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J. Biol. Chem. 275 : 20632 20637.
5. Vitovski, S. et al. 2007. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J. Biol. Chem. 282 : 31601 31609.
6. Spierings, D.C. et al. 2004. Tissue distribution of the death ligand TRAIL and its receptors. J. Histochem. Cytochem. 52 : 821 831.
7. Walczak, H. T.L. Haas. 2008. Biochemical analysis of the native TRAIL death-inducing signaling complex. Methods Mol. Biol. 414 : 221 239.
8. Youle, R.J. A. Strasser. 2008. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9 : 47 59.
9. Kavurma, M.M. et al. 2008. Trail stimulates proliferation of vascular smooth muscle cells via activation of NF-kappa B and induction of insulin-like growth factor-1 receptor. J. Biol. Chem. 3 : 3.
10. Song, J.H. et al. 2007. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res. 67 : 6946 6955.
11. Siegmund, D. et al. 2007. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells. Cell Signal. 19 : 1172 1184. Epub 2007 Jan 3.
12. Tran, S.E. et al. 2001. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 276 : 16484 16490.
13. Mercurio, F. et al. 1997. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278 : 860 866.
14. Zandi, E. et al. 1997. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91 : 243 252.
15. Ishimura, N. et al. 2006. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 290 : G129 136.
16. Soderstrom, T.S. et al. 2002. Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J. Immunol. 169 : 2851 2860.
17. Lee, T.J. et al. 2006. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem. Biophys. Res. Commun. 351 : 1024 1030.
18. Frese, S. et al. 2003. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 22 : 5427 5435.
19. Muhlenbeck, F. et al. 1998. TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J. Biol. Chem. 273 : 33091 33098.
20. Zhang, L. et al. 2004. Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. Cancer Biol. Ther. 3 : 296 301.
21. Corazza, N. et al. 2006. TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J. Clin. Invest. 116 : 2493 2499.
22. Abayasiriwardana, K.S. et al. 2007. Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther. 6 : 2766 2776.
23. Zhang, X. et al. 2004. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 64 : 7086 7091.
24. Siegmund, D. et al. 2002. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol Med. 8 : 725 732.
25. Ng, C.P. B. Bonavida. 2002. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol Cancer Ther. 1 : 1051 1058.
26. Cummins, J.M. et al. 2004. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res. 64 : 3006 3008.
27. Walczak, H. et al. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 : 157 163.
28. Rothstein, J.L. H. Schreiber. 1988. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc. Natl. Acad. Sci. USA 85 : 607 611.
29. Kondo, T. et al. 1997. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3 : 409 413.
30. Fuster, J.J. et al. 2007. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol. Med. 13 : 192 199. Epub 2007 Mar 23.
31. Syed, V. et al. 2007. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J. Cell Biochem. 102 : 442 452.
32. Verbrugge, I. et al. 2008. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene 27 : 574 584.
33. Ganten, T.M. et al. 2006. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res. 12 : 2640 2646.
34. Liu, X. et al. 2004. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 64 : 5078 5083.
35. Roue, G. et al. 2007. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J. Immunol. 178 : 1923 1930.
36. Voortman, J. et al. 2007. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther. 6 : 2103 2112.
37. Ravi, R. et al. 2004. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res. 64 : 9105 9114.
38. Xia, S. et al. 2007. Ribotoxic stress sensitizes glioblastoma cells to death receptor induced apoptosis: requirements for c-Jun NH2-terminal kinase and Bim. Mol Cancer Res. 5 : 783 792.
39. MacFarlane, M., G.M. Cohen M. Dickens. 2000. JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: differential requirements for caspase activation. Biochem. J. 348 (Pt 1 93 101.
40. Lin, Y. et al. 2000. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol. 20 : 6638 6645.
41. Varfolomeev, E. et al. 2005. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 280 : 40599 40608.
42. Vivo, C., W. Liu V.C. Broaddus. 2003. c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J. Biol. Chem. 278 : 25461 25467.
43. Leung, K.T. et al. 2008. Activation of the JNK pathway promotes phosphorylation and degradation of BimEL a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis 3 : 3.
44. Cai, B. et al. 2006. p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65. J. Biol. Chem. 281 : 25215 25222.
45. Takeda, K. et al. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7 : 94 100.
46. Cretney, E. et al. 2002. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168 : 1356 1361.
47. Mundt, B. et al. 2005. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 54 : 1590 1596.
48. Jo, M. et al. 2000. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6 : 564 567.
49. Zheng, S.J. et al. 2004. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J. Clin. Invest. 113 : 58 64.
50. Takeda, K. et al. 2000. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. USA 97 : 5498 5503.
51. Kaufmann, T. et al. 2007. The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell 129 : 423 433.
52. Yin, X.M. et al. 1999. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400 : 886 891.
53. Zhao, Y. et al. 2001. Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-alpha-induced liver injury. J. Biol. Chem. 276 : 27432 27440.
54. Malhi, H. et al. 2007. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 56 : 1124 1131.
55. Lei, K. and R.J. Davis. 2003. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc. Natl. Acad. Sci. USA 100 : 2432 2437.
56. Corazza, N. et al. 2004. TRAIL and thymocyte apoptosis: not so deadly? Cell Death Differ. 11 (Suppl 2 S213 215.